Humacyte Inc (HUMA)
3.99
+0.09
(+2.31%)
USD |
NASDAQ |
Apr 26, 16:00
3.98
-0.01
(-0.25%)
After-Hours: 20:00
Humacyte Cash from Investing (TTM): -0.173M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.173M |
September 30, 2023 | 5.189M |
June 30, 2023 | 5.471M |
March 31, 2023 | 3.715M |
December 31, 2022 | 4.845M |
Date | Value |
---|---|
September 30, 2022 | -8.412M |
June 30, 2022 | -8.284M |
March 31, 2022 | -8.213M |
December 31, 2021 | -8.22M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-8.412M
Minimum
Sep 2022
5.471M
Maximum
Jun 2023
-1.565M
Average
-0.173M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
Adial Pharmaceuticals Inc | -- |
Gritstone Bio Inc | 102.34M |
Precision BioSciences Inc | 5.829M |
Puma Biotechnology Inc | -19.12M |
Revance Therapeutics Inc | 109.74M |